SSStephan Stilgenbauer

Stephan Stilgenbauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephan Stilgenbauer has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”

    by Alessandra Tedeschi, Raul Cordoba, Alessandra Ferrajoli, George Follows, Anna Maria Frustaci, Anne Sophie Michallet, Talha Munir, Susan O'BRien, John F. Seymour, Tait Shanafelt, et al.

  • Open Access

    In‐frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL

    by Šárka Pavlová, Johana Gombíková, Silvia Petrezsélyová, Libor Macůrek, Marcela Ženatová, Marie Zádrapová, Anna Panovská, Eva Zapletalová, Blanca Ferrer Lores, Alicia Serrano Alcalá, et al.

    The prognostic and predictive impact of TP53 variants in leukemia led to their inclusion in diagnostic and treatment guidelines, increasing the demand for rapid, reliable laboratory analysis, interpretation, and reporting. While most TP53 variants identified in tumor samples can be interpreted using data from large‐scale functional studies, evidence regarding the impact of in‐frame deletions and insertions not disturbing the reading frame remains limited. Consequently, the classification of somatic in‐frame variants often relies on expert judgment rather than standardized criteria. To address this gap, we collected in‐frame TP53 variants identified during routine diagnostic testing in laboratories within the TP53 Network of Education and Research Initiative on Chronic Lymphocytic Leukemia (ERIC). We analyzed 60 leukemia samples from 13 laboratories, comprising 54 distinct variants. Initial classification using existing data and interpretation guidelines assigned these variants predominantly to the category of variants of uncertain significance. Functional analyses using a yeast‐based transactivation assay, complemented by testing selected variants in the TP53 ‐knockout RPE1 cell line, showed a nonfunctional phenotype for the vast majority of in‐frame TP53 variants. This indicates that most in‐frame alterations detected in leukemia samples are functionally deleterious, as further supported by their association with second‐allele inactivation and frequent clonal expansion in relapse. With respect to variant localization, we observed that 49 variants located within the core region of the DNA‐binding domain showed complete loss of transactivation function. The five variants located downstream of codon 286 exhibited heterogeneous functional phenotypes depending on their localization and the experimental system used. In conclusion, the integration of our findings with published functional data supports the interpretation that in‐frame TP53 variants within the core DNA‐binding domain identified in tumor samples are likely pathogenic. Conversely, interpretation of less frequent in‐frame variants outside this region requires integration of multiple evidence, including functional studies, published literature, and curated variant databases. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

  • Open Access

    IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

    by Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Palash C. Maity, Armin Riecke, Christof Schneider, Billy M. C. Jebaraj, Rashmi P. Dheenadayalan, Hassan Jumaa, Marc Young, et al.

    IGLV3‐21 R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors. Here, we analyzed samples from the phase 3 CLL12 study that compared ibrutinib vs. placebo in untreated early‐stage CLL patients with intermediate to very high risk of disease progression, while patients with low risk of disease progression were allocated to watch‐and‐wait (w&w). Four detection methods (targeted next‐generation sequencing, Sanger sequencing, multiplex IGLV3‐21 R110 ‐specific PCR, and flow cytometry) were compared, yielding highly consistent results. Overall, 34/515 (6.6%) patients had productive IGLV3‐21 rearrangements: 5/152 (3.3%) in w&w, 15/181 (8.3%) in placebo, and 14/182 (7.7%) in the ibrutinib group. Of these, 25 were IGLV3‐21 R110 ‐positive (3/5, 12/15, and 10/14). IGLV3‐21 R110 was associated with shorter event‐free survival (EFS) across all arms: w&w (hazard ratio [HR] 17.03, 95% confidence interval [CI 95%]: 4.99–58.13, P < 0.001), placebo (HR 2.31, CI 95%: 1.16–4.6, P = 0.017), and ibrutinib (HR 2.99, CI 95%: 1.17–7.65, P = 0.023). Multivariable analysis identified IGLV3‐21 R110 as an independent prognostic factor for shorter EFS (HR 3.18, CI 95%: 1.73–5.83, P < 0.001). Notably, IGLV3‐21 R110 was associated with reduced clinical effectiveness of ibrutinib. Ca 2+ ‐flux and cell viability assays using patient‐derived BCRs expressed in murine B‐cells confirmed reduced ibrutinib efficacy in IGLV3‐21 R110 cases, especially regarding inhibition of antigen‐stimulated signaling. In summary, IGLV3‐21 R110 is an independent prognostic factor for shorter EFS in early‐stage CLL and reduces ibrutinib effectiveness clinically and in vitro.

  • Open Access

    Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms

    by Lorenz Thurner, Natalie Fadle, Bernhard Thurner, Igor Age Kos, Moritz Bewarder, Evi Regitz, Birgit Bette, Yvan Fischer, Vadim Lesan, Torben Rixecker, et al.

    SARS-CoV-2 infection affects multiple immune mechanisms and leads to severe COVID-19 and death, in part related to infection-induced or pre-existing autoantibodies. Here, we describe severe COVID-19 to associate with autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) and progranulin (PGRN), endogenous antagonists of IL-1 and TNF signaling, respectively. These autoantibodies coincide with hyperphosphorylation of IL-1Ra (Thr111) or PGRN (Ser81), form immune complexes independent of phosphorylation, reduce antigen plasma levels, and permit enhanced IL-1 and TNF signaling. Using phage-display selected Fabs specific for hyperphosphorylated isoforms, we track phospho-antigens and autoantibodies in a German national pandemic network cohort. Most seropositive patients show both autoantibodies. Levels peak at baseline and decline over 12 months, with phospho-antigens decreasing before autoantibodies. Seropositivity associates with hyperinflammation and cytokine profiles. Importantly, signaling by key inflammatory cytokines induce IL-1Ra and PGRN hyperphosphorylation in healthy monocytes, but require up to 1000-fold higher doses than in monocytes from previously seropositive severe COVID-19 survivors.


  • Open Access

    CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion

    by Junnan Liu, Wencheng Jiang, Xue Wang, Anca Azoitei, Hengchuan Liu, Gregoire Najjar, Kuangzheng Liu, Michael Karl Melzer, Stephan Stilgenbauer, Mohamed Elati, et al.

    Background: Bladder cancer (BC) can be characterized clinically as either non-muscle-invasive (NMIBC) or muscle-invasive (MIBC). While NMIBC generally has a favorable prognosis, MIBC is characterized by high morbidity and mortality. Understanding the molecular determinants of tumor invasion is critical, yet research is hampered by the limitations of current experimental models. Standard assays such as the Boyden chamber lack physiological complexity, while porcine bladder models suffer from tissue contamination and genetic variability. There is an urgent need for reliable models that mimic the intact tissue architecture. Methods: We established a unique ex vivo tissue invasion model (EXTIM) to evaluate the invasive capacity of BC cells within a largely intact tissue context, using freshly prepared bladders from mice. The invasiveness of human BC cells (RT4, T24, UMUC3) and the immortal urothelial cell strain (Y235T) was comparably evaluated using EXTIM, the Boyden chamber, and porcine models. Gene knockdown or ectopic expression of GJB3 or ORP3 indicated the suitability of EXTIM to investigate the impact of specific factors on tumor cell invasion. To identify novel genetic regulators of cell invasion, we combined EXTIM with a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 knockout screen. Additionally, we utilized the EXTIM to perform a pharmacological screen of a small molecule library comprising 90 substances to identify compounds capable of suppressing BC cell dissemination. Results: Importantly, by combining EXTIM with genomewide CRISPR-Cas9 screening, we identified several candidate genes involved in BC progression. Notably, discoidin domain receptor tyrosine kinase 1 (DDR1) was identified as a functional inhibitor of tumor cell invasion. Furthermore, the small-molecule screen revealed that PD-156707, a selective antagonist of the endothelin receptor A (ETA), significantly suppresses cancer cell invasion within the EXTIM environment. Conclusions: EXTIM serves as a robust and physiologically relevant tool for assessing tumor cell invasion and migration under ex vivo conditions. EXTIM can be used to identify factors involved in the progression of invasive BC by high-throughput genetic screenings in an ex vivo organ culture system, by culturing cells after transmigration through the bladder tissue. Moreover, the impact of specific genetic factors in the process of tumor cell dissemination can be assessed by placing bladders from genetically modified mice into the EXTIM.

  • Open Access

    The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia

    by Cosima Drewes, Cristina López, Nnamdi Okeke, Billy Jebaraj, Christoph Wiegreffe, Isabelle Kraus, Sina Hillebrecht, Amani Awada, Susanne Bens, Emil Chteinberg, et al.

    Activation of oncogenes by hijacking immunoglobulin gene loci ( IG ) enhancers via chromosomal translocation is a common pathogenetic mechanism in B-cell malignancies, affecting 5–10% of chronic lymphocytic leukemia (CLL). The oncogenic partners in many of these cases remain unidentified. Therefore, we conducted a comprehensive analysis of 144 CLL samples with IGH- translocation excluding IGH :: BCL2 , IGH :: CCND1 , IGH :: BCL3 and IGH :: MYC . By combining fluorescence in situ hybridization (FISH) with whole-genome, targeted sequencing, and RNA expression profiling, we identified 25 IG -translocation partners; 12 were previously unreported. Of 142 cases, 107 (75%) displayed an unmutated IGHV . Genetic profiling showed a heterogenous distribution of chromosomal aberrations and recurrently mutated genes across the groups. Of 41 informative cases, 32 (78%) exhibited breakpoints driven by aberrant class-switch recombination (CSR), with prominent involvement of IGHM (9/41) and IGHG3 (9/41). Three cases with unmutated IGHV carried a juxtaposition of the IGH locus 5’ to the intact NKX2.6 gene in chromosome 8p21.2 due to illegitimate VDJ recombination, associated with significant ectopic upregulation of NKX2.6 transcriptional expression (FDR < 0.001, logFC: 15). Similarly, METRNL , located at the telomere of chromosome 17q25, was identified as a translocation partner gene in four cases. Our findings expand the spectrum of the oncogenic translocation partners targeting IGH in CLL.

  • Open Access

    Short and complex—Telomeres and genomes in CLL

    by Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer

    Chronic lymphocytic leukaemia (CLL) with complex karyotype (CK) represents a high‐risk subgroup, often associated with refractory disease. In a patient cohort enriched for CK CLL, short telomeres were found to be associated with poor‐risk characteristics such as unmutated immunoglobulin heavy chain variable region (IGHV), del(11q)/del(17p), CK/genomic complexity (GC) and chromothripsis. The presence of short telomeres was associated with shorter time to first treatment (TTFT) in the full cohort and in cases with CK or del(17p), and in multivariable analysis as a prognostic factor, indicating the potential importance of this biomarker for CLL risk stratification. Commentary on Ramos‐Campoy et al. Exploring the synergy between telomere length and genomic complexity in CLL. Br J Haematol 2026; 208:1121–1126.

  • Open Access

    Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia

    by Raúl Córdoba, Stephan Stilgenbauer, Paolo Ghia, Alessandra Tedeschi, Lindsey Roeker, Myriam Rodriguez‐Couso, Stephen P. Mulligan, Samir Kanaan Nabhan, Jan Rynne, Teresa López‐Fernández

    Advancements in the understanding of chronic lymphocytic leukemia (CLL) have transformed patient care, leading to the development of novel targeted therapies. Traditionally, patient fitness for treatment was based on the tolerability of chemoimmunotherapy such as fludarabine–cyclophosphamide–rituximab. As the CLL patient population is predominantly older, age has historically been a major factor in how a physician selects a patient's treatment. However, as a patient's fitness goes beyond age, the definition of patient fitness should also evolve. Here, we provide suggestions for the current best practice on assessing fitness for treating CLL. Considerations for treatment include assessment of polypharmacy, history of infections, cardiovascular and renal comorbidities, functional status, cognitive and psychological status, nutritional status, and social support. The flow of assessments can start with a typical clinical evaluation followed by geriatric, cardiovascular, and renal reviews, if needed, and include collecting a patient's full history to evaluate their risk of complications with specific CLL treatments. The severity of a patient's cardiovascular profile can range from low to high risk; for those at high risk, collaboration with a cardiologist is recommended. Geriatric assessment is advised to determine baseline frailty and resilience to tolerate treatments, to avoid inappropriate treatment or undertreating patients based on chronological age, and to align the patient's fitness status with the most optimal treatment. Continuous monitoring and assessment, regardless of therapy, are recommended. Patient preferences are also integral to this decision‐making process. Looking beyond a patient's age and basing treatment selection on their fitness is key in the new era of treatment in CLL.


  • Open Access

    Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts

    by Albert Kallon Koroma, Karmveer Singh, Yongfang Wang, Linda Krug, Philipp Haas, Meinhard Wlaschek, Vadim Sakk, Tanja Schuster, Daniel Fürst, Hubert Schrezenmeier, et al.

    Senescent fibroblasts accumulate in the connective tissue of all organs and promote organ aging and aging‐related diseases. The underlying mechanisms for the accumulation of senescent fibroblasts are poorly understood. Natural killer (NK) cells of innate immunity play a critical role in the removal of tissue resident senescent cells. We here show that NK cells from old adults and old mice fail to efficiently remove senescent fibroblasts. This is due to severely reduced perforin and granzyme B release from aged NK cells where perforin is responsible for inducing holes in the membrane of senescent fibroblasts through which granzyme B enters enforcing cell death of senescent fibroblasts. We demonstrate elevated activation of the small Cdc42 Rho GTPase in aged NK cells to be responsible for the disruption of the microtubular organization which is essential for the proper release of perforin and granzyme B and for energy homeostasis. Attenuation of the elevated activity of Cdc42 in aged human NK cells with CASIN, a small molecule Cdc42 inhibitor, rebalances Cdc42 activity to a young level. Rebalancing of Cdc42 restores proper perforin and granzyme B release and attenuates reduced ATP levels in aged NK cells resulting in an attenuated “youthful” cytotoxicity of aged NK cells against senescent cells. Collectively, we identified a previously unreported molecular mechanism underlying functional impairment of NK cells from older adults. In perspective, our data hold promise to develop novel strategies against age‐related disorders driven by tissue‐resident senescent fibroblasts.


  • Open Access

    Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

    by Linda Simon, Vladan Vucinic, Kai Rejeski, Maria-Luisa Schubert, Enver Aydilek, Eva-Maria Wagner-Drouet, Olaf Penack, Malte von Bonin, Bastian von Tresckow, Marcel Teichert, et al.